No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Drugmaker Astrazeneca's raredisease unit Alexion said on Thursday that Ultomiris had won accelerated US approval as the first treatment aimed at reducing protein levels in the urine of adults with primary IgA nephropathy.
Astrazeneca said the decision followed a priority review by the Food and Dug Administration and was based on interim Phase III data showing Ultomiris delivered a 43.4% reduction in proteinuria versus placebo at 34 weeks.
However, the regulator stressed that it has not yet been proven whether the drug slows longterm kidney decline, with continued approval dependent on results from the ongoing I CAN trial, which will measure kidneyfunction change at week 106.
Ultomiris, given by IV infusion every eight weeks after a loading dose, was being studied as a potential longterm therapy for IgA nephropathy, a rare kidney condition that can lead to chronic disease and, in many cases, kidney failure.
Latebreaking data from the I CAN trial will be presented at Kidney Week 2026, with Astrazeneca aiming to convert the accelerated approval into full approval once confirmatory results become available.
As of 1135 BST, Astrazeneca shares were down 0.30% at 12,576p.
Reporting by Iain Gilbert at Sharecast.com
See latest RNS at Sharecast
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.